Abstract
Sucralose (a.k.a. Splenda when combined with dextrose and maltodextrin) is a popular nonnutritive sweetener (NNS) found in several beverages marketed for health benefits and fitness. This article examines the mechanistic aspects of sucralose’s metabolic effects on satiety, obesity, glycemic control, and adipogenesis, along with gut dysbiosis, inflammation, and disruption of intestinal permeability. Some evidence suggests that sucralose may also alter appetite regulation, taste perception, and energy intake. Additionally, there are safety concerns regarding its carcinogenic potential and its epigenetic effect on the fetus due to consistent maternal consumption. Based on current findings of NNS, it was concluded that sucralose may be of use in weight reduction in the short term as an NNS. However, this needs to be weighed against the possible long-term metabolic side effects and safety precautions.
Keywords
Get full access to this article
View all access options for this article.
